Publications

Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer (2018 Innate Killer Summit)

Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018

Initial Clinical Data of FATE-NK100 for Relapsed/Refractory AML (SITC 2017 Annual Meeting)

Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting

2017 AACR Poster

FATE NK-100: A Novel NK Cell-Mediated Cancer Therapy

2018 AACR Poster

AACR18 FT500 Poster Session

59th American Society of Hematology (ASH) Annual Meeting and Exposition

FT516 iPSC-derived hnCD16 NK Cell Cancer Immunotherapy

2018 AACR Press Program and Poster Presentations

AACR18 FT819 Press Conference
AACR18 FT819 Poster Session

PROTECT Phase 1 Results at Day 100 (ASH 2017)

Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage

Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune (EBMT 2018)

Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™

2017 ISSCR Poster

Off-the-shelf Immunoregulatory Cells Generated from Human Induced Pluripotent Stem Cells for the Treatment of Autoimmune and Inflammatory Diseases

2016 ADA Poster

Using Pharmacologically Programmed CD34⁺ Cells for the Treatment of Type 1 Diabetes

Stem Cell Reports

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells